Skip to main content
. 2019 Dec 30;7(1):e000742. doi: 10.1136/bmjdrc-2019-000742

Table 1.

Proportion of real-world SGLT2i new users excluded from cardiovascular outcome trials

Real-world data in Taiwan
All Canagliflozin Dapagliflozin Empagliflozin
N (%) N N (%) N (%)
All patients 11 650 (100.0) 1091 (9.4) 4748 (40.8) 5811 (49.9)
Comparison of CANVAS program
Excluded for any of the following: 4977 (42.7) 443 (40.6) ---- ----

  1. Aged ≥30 years without CVD history (unstable angina, CAD, ischemic stroke, heart failure and MI) or

  2. Aged ≥50 years without dyslipidemia, duration of diabetes ≥10 years or smoker

 2811 (24.1) 240 (22.0) ---- ----
 HbA1c >10.5% or HbA1c <7% 2917 (25.0) 263 (24.1) ---- ----
 eGFR <30 mL/min/1.73 m2 166 (1.4) 27 (2.5) ---- ----
Comparison of DECLARE-TIMI 58 trial
Excluded for any of the following: 5773 (49.6) ---- 2270 (47.8) ----

  1. Aged ≥40 years without CVD history (CAD, ischemic stroke, lower extremity amputation and MI) or

  2. Males aged ≥55 years and females aged ≥60 years without hypertension, dyslipidemia or smoker

 3979 (34.2) ---- 1740 (36.6) ----
 HbA1c >12% or HbA1c <6.5% 704 (6.0) ---- 257 (5.4) ----
 eGFR <60 mL/min/1.73 m2 1544 (13.3) ---- 441 (9.3) ----
Comparison of EMPA-REG OUTCOME trial
Excluded for any of the following: 9466 (81.3) ---- ---- 4611 (79.3)
 No CVD history (unstable angina, CAD, stroke, lower extremity amputation, MI and PAD) 8480 (72.8) ---- ---- 4006 (68.9)
 HbA1c >10% or HbA1c <7% 3402 (29.2) ---- ---- 1837 (31.6)
 eGFR <30 mL/min/1.73 m2 166 (1.4) ---- ---- 88 (1.5)
Comparison of VERTIS-CV trial
Excluded for any of the following: 9411 (80.8) ---- ---- ----
 Aged ≥40 years without CVD history (unstable angina, CAD, ischemic stroke, MI and PAD) 8577 (73.6) ---- ---- ----
 HbA1c >10.5% or HbA1c <7% 2917 (25.0) ---- ---- ----
 eGFR <30 mL/min/1.73 m2 166 (1.4) ---- ---- ----
 BMI<18 kg/m2 125 (1.1) ---- ---- ----

BMI, body mass index; CAD, cardiovascular artery disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; MI, myocardial infarction; PAD, peripheral artery disease.